<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643459</url>
  </required_header>
  <id_info>
    <org_study_id>HerlevH01</org_study_id>
    <nct_id>NCT02643459</nct_id>
  </id_info>
  <brief_title>Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage</brief_title>
  <acronym>suPAR</acronym>
  <official_title>Introduction of Soluble Urokinase Plasminogen Activating Receptor in Acute Care as a Prognostic Biomarker to Strengthen Risk Stratification of Acutely Admitted Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Will clinical outcome for patients be improved if triage in Acute wards and Emergency rooms&#xD;
      is supplemented with a prognostic biomarker?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a health care system where the general population is growing, more patients are living&#xD;
      with chronic conditions and the hospitals are reducing beds and length of stay, it is crucial&#xD;
      to perform safe and fast risk stratification of patients presenting in the Emergency&#xD;
      departments. Risk stratification is currently performed with a combination of measurement of&#xD;
      the vital signs and assessment of the primary complaint. The aim of the current study is to&#xD;
      assess whether the supplement of biomarkers can improve the risk stratification in regard to&#xD;
      mortality, readmissions and improve overall patient flow in the Emergency departments.&#xD;
      Soluble urokinase plasminogen activating receptor (suPAR) is the soluble form of&#xD;
      urokinase-type plasminogen activator receptor (uPAR). uPAR is present on various&#xD;
      immunological active cells, as well as endothelia and smooth muscle cells. It is believed&#xD;
      that suPAR mirrors the inflammatory response in patients. Previous studies have shown a&#xD;
      strong association with mortality and severity of disease in a broad variety of conditions&#xD;
      (infection, hepatic-, renal-, cardiac- and lung disease) as well as a possible marker of&#xD;
      disease development in the general population. These abilities indicate that suPAR although&#xD;
      unspecific would be ideal to identify patients at high- and at low-risk. The aim is to target&#xD;
      interventions and limited clinical focus where it is most beneficial. In unselected patients&#xD;
      suPAR is one of the strongest prognostic biomarker available to date.&#xD;
&#xD;
      It is not known whether information on prognosis in the Emergency department can be used to&#xD;
      prevent death, serious complications or reduce admissions and readmissions.&#xD;
&#xD;
      The purpose of the current study is to examine if introduction of the biomarker suPAR and&#xD;
      education of doctors in the meaning of suPAR levels and association to disease, can reduce&#xD;
      mortality, admissions and readmission in patients referred to the emergency rooms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">April 6, 2017</completion_date>
  <primary_completion_date type="Actual">April 6, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>10 months after the inclusions period ends mortality data will be assessed</time_frame>
    <description>Time frame starts at the beginning of the index admission, defined as first admission in the study period. Patients will be followed using central registers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>1 months after index admission mortality data will assessed</time_frame>
    <description>Mortality within 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Discharges From the Emergency Room Within 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>How many patients are discharged directly from the ED</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Admissions to the Medical Ward</measure>
    <time_frame>30 days</time_frame>
    <description>Number of Participants with Admissions to the Medical War</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With an Admission to the Intensive Care Unit</measure>
    <time_frame>30 days</time_frame>
    <description>Number of Participants with transfer to the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With New Cancer Diagnosis in Control vs Intervention Groups</measure>
    <time_frame>10 months after inclusion period ends</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay During Admission.</measure>
    <time_frame>30 days</time_frame>
    <description>Length of stay in days during the admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Readmissions</measure>
    <time_frame>90 days</time_frame>
    <description>Patients will be followed using central registers. All new admissions within 90 days of the same patient is defined as readmissions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20000</enrollment>
  <condition>Triage</condition>
  <condition>Risk Stratification With Biomarker</condition>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no suPAR measurement. Standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>suPAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>suPAR measurement</intervention_name>
    <description>The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.</description>
    <arm_group_label>suPAR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting acutely to the Acute ward/Emergency department and have blood&#xD;
             samples done which include both Hemoglobin, C reactive protein and Creatinine within 6&#xD;
             hours of registration within the study period. The study is carried out in 2 Hospitals&#xD;
             in the Capital of Denmark.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients presenting in Pediatric, Gynecological or Obstetric units. Patients not being&#xD;
             examined with blood samples.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kasper K Iversen, MD, DMSci</last_name>
    <role>Study Director</role>
    <affiliation>Department of Cardiology, Herlev Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital, Department of Cardiology</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <results_first_submitted>February 25, 2019</results_first_submitted>
  <results_first_submitted_qc>February 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2021</results_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Martin Schultz</investigator_full_name>
    <investigator_title>MD, P.h.D student</investigator_title>
  </responsible_party>
  <keyword>Triage</keyword>
  <keyword>Risk stratification</keyword>
  <keyword>Acute care</keyword>
  <keyword>suPAR</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02643459/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Conventional</title>
          <description>no suPAR measurement. Standard care.</description>
        </group>
        <group group_id="P2">
          <title>suPAR</title>
          <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7901"/>
                <participants group_id="P2" count="8900"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7901"/>
                <participants group_id="P2" count="8900"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional</title>
          <description>no suPAR measurement. Standard care.</description>
        </group>
        <group group_id="B2">
          <title>suPAR</title>
          <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7901"/>
            <count group_id="B2" value="8900"/>
            <count group_id="B3" value="16801"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="20.7"/>
                    <measurement group_id="B2" value="60.4" spread="20.8"/>
                    <measurement group_id="B3" value="60.6" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4175"/>
                    <measurement group_id="B2" value="4689"/>
                    <measurement group_id="B3" value="8864"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3726"/>
                    <measurement group_id="B2" value="4211"/>
                    <measurement group_id="B3" value="7937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7901"/>
                    <measurement group_id="B2" value="8900"/>
                    <measurement group_id="B3" value="16801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7901"/>
                    <measurement group_id="B2" value="8900"/>
                    <measurement group_id="B3" value="16801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All Cause Mortality</title>
        <description>Time frame starts at the beginning of the index admission, defined as first admission in the study period. Patients will be followed using central registers.</description>
        <time_frame>10 months after the inclusions period ends mortality data will be assessed</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>no suPAR measurement. Standard care.</description>
          </group>
          <group group_id="O2">
            <title>suPAR</title>
            <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR.</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <description>Time frame starts at the beginning of the index admission, defined as first admission in the study period. Patients will be followed using central registers.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7901"/>
                <count group_id="O2" value="8900"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1126"/>
                    <measurement group_id="O2" value="1241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <description>Mortality within 30 days</description>
        <time_frame>1 months after index admission mortality data will assessed</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>no suPAR measurement. Standard care.</description>
          </group>
          <group group_id="O2">
            <title>suPAR</title>
            <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR.</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <description>Mortality within 30 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7901"/>
                <count group_id="O2" value="8900"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                    <measurement group_id="O2" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Discharges From the Emergency Room Within 24 Hours</title>
        <description>How many patients are discharged directly from the ED</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>no suPAR measurement. Standard care.</description>
          </group>
          <group group_id="O2">
            <title>suPAR</title>
            <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.&#xD;
suPAR measurement: The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Discharges From the Emergency Room Within 24 Hours</title>
          <description>How many patients are discharged directly from the ED</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7901"/>
                <count group_id="O2" value="8900"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3934"/>
                    <measurement group_id="O2" value="4352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Admissions to the Medical Ward</title>
        <description>Number of Participants with Admissions to the Medical War</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>no suPAR measurement. Standard care.</description>
          </group>
          <group group_id="O2">
            <title>suPAR</title>
            <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.&#xD;
suPAR measurement: The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Admissions to the Medical Ward</title>
          <description>Number of Participants with Admissions to the Medical War</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7901"/>
                <count group_id="O2" value="8900"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3500"/>
                    <measurement group_id="O2" value="3738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With an Admission to the Intensive Care Unit</title>
        <description>Number of Participants with transfer to the ICU</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>no suPAR measurement. Standard care.</description>
          </group>
          <group group_id="O2">
            <title>suPAR</title>
            <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.&#xD;
suPAR measurement: The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an Admission to the Intensive Care Unit</title>
          <description>Number of Participants with transfer to the ICU</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7901"/>
                <count group_id="O2" value="8900"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1027"/>
                    <measurement group_id="O2" value="1157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With New Cancer Diagnosis in Control vs Intervention Groups</title>
        <time_frame>10 months after inclusion period ends</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>no suPAR measurement. Standard care.</description>
          </group>
          <group group_id="O2">
            <title>suPAR</title>
            <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.&#xD;
suPAR measurement: The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With New Cancer Diagnosis in Control vs Intervention Groups</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7901"/>
                <count group_id="O2" value="8900"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="687"/>
                    <measurement group_id="O2" value="917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay During Admission.</title>
        <description>Length of stay in days during the admission</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>no suPAR measurement. Standard care.</description>
          </group>
          <group group_id="O2">
            <title>suPAR</title>
            <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.&#xD;
suPAR measurement: The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay During Admission.</title>
          <description>Length of stay in days during the admission</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7901"/>
                <count group_id="O2" value="8900"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.53" spread="8.7"/>
                    <measurement group_id="O2" value="4.39" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Readmissions</title>
        <description>Patients will be followed using central registers. All new admissions within 90 days of the same patient is defined as readmissions.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>no suPAR measurement. Standard care.</description>
          </group>
          <group group_id="O2">
            <title>suPAR</title>
            <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.&#xD;
suPAR measurement: The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Readmissions</title>
          <description>Patients will be followed using central registers. All new admissions within 90 days of the same patient is defined as readmissions.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7901"/>
                <count group_id="O2" value="8900"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="687"/>
                    <measurement group_id="O2" value="917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Data on all outcomes were collected from national registries.</desc>
      <group_list>
        <group group_id="E1">
          <title>Conventional</title>
          <description>no suPAR measurement. Standard care.</description>
        </group>
        <group group_id="E2">
          <title>suPAR</title>
          <description>suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1126" subjects_at_risk="7901"/>
                <counts group_id="E2" subjects_affected="1241" subjects_at_risk="8900"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7901"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8900"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="700" subjects_at_risk="7901"/>
                <counts group_id="E2" subjects_affected="777" subjects_at_risk="8900"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>New cancer diagnosis</sub_title>
                <counts group_id="E1" events="700" subjects_affected="700" subjects_at_risk="7901"/>
                <counts group_id="E2" events="777" subjects_affected="777" subjects_at_risk="8900"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Martin Schultz</name_or_title>
      <organization>Herlev Hospital, Department of Cardiology</organization>
      <phone>004538683868</phone>
      <email>martin.schultz@regionh.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

